Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
- First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic targets with injections
-
People using Omnipod 5 had significantly improved HbA1c levels (average reduction of -
0.8% ) compared with those using multiple daily injections with a continuous glucose monitor at the end of the three-month study period - Omnipod 5 was also linked to dramatic improvements in glucose with people spending an average of +5.4 hours more per day with glucose levels in the target range without an increase in hypoglycemia
The RADIANT study is the first randomized controlled trial to evaluate the direct transition from multiple daily injections (MDI) to an automated insulin delivery (AID) system in adults and children with type 1 diabetes, as well as being the first to assess the safety and efficacy of an AID system paired with an Abbott FreeStyle Libre® 2 family sensor. The study found that for adults and children not previously meeting clinical targets for HbA1c on MDI, Insulet’s Omnipod 5 AID System provided clinically significant improvements in HbA1c compared with MDI used with a continuous glucose monitor (CGM).
Despite advances in diabetes technology, MDI is the predominant therapy option for type 1 diabetes1, and it is estimated that 35 years of healthy life are being lost on average per person globally due to this condition2. Data from the
The RADIANT study included 188 people aged 4 to 70 years with type 1 diabetes and HbA1c levels of
Participants began with an average HbA1c level of
“Omnipod 5 is changing the lives of an estimated 365,000 users worldwide by eliminating the need for injections and reducing the burden of diabetes. Results from this randomized controlled trial build on our previous studies and once again clearly demonstrate the significant therapeutic benefits for people who require insulin to live and switch from injections to Omnipod 5,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer.
In addition to improving their HbA1c, Omnipod 5 users spent an additional 5.4 hours per day with glucose levels in the target range (70-180mg/dL) compared with MDI plus CGM users, resulting in a final average time in range of
“The RADIANT population was a cohort of individuals who, despite multiple daily injections and CGM, were not achieving target HbA1c levels. These participants, many of whom were waiting for a tubeless AID option, were able to safely transition directly from MDI to Omnipod 5 and achieve significant improvements in glucose levels,” said Dr. Emma G. Wilmot, Associate Professor at the University of
“Omnipod 5 has proved clinical efficacy in people living with type 1 diabetes. The RADIANT experience showed us that it was easy to implement in pump naïve patients, with very good results. It encourages us to pursue a direct switch from multiple daily injections to automated insulin delivery so patients can immediately receive the clear benefits, without a long period of manual pump treatment,” said Professor Hélène Hanaire, head of the Department of Diabetology, Metabolic Diseases and Nutrition of the University Hospital of
Approximately 5.2 million people live with type 1 diabetes in the 25 countries Insulet currently serves globally.5 That includes the U. S. and 10 countries outside the
- 2024. Data on file. Seagrove Partners LLC.
- Type 1 Diabetes Index. https://www.t1dindex.org Accessed February 11, 2025
- Gandhi et al. T1D Exchange Quality Improvement Collaborative; Insulin Pump Utilization in 2017–2021 for More Than 22,000 Children and Adults With Type 1 Diabetes: A Multicenter Observational Study. Clin Diabetes 15 January 2024; 42 (1): 56–64. https://doi.org/10.2337/cd23-0055.
- DCCT Research Group; The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. NEJM 30 September 1993; 329 (14): 977-86. https://doi.org/10.1056/nejm199309303291401
- Insulet data on file, January 2025
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319816630/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7718
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation